Integral Molecular

In this article: Why shouldn't specificity testing stop at the membrane? Why do secreted proteins require a different platform? What's in the SPL? When should I add SPL to my MPA project? This article is part 8 of a series about specificity testing. Be su

In this article: How was the MPA library designed? What's in the library beyond the canonical membrane proteome? How well does the MPA represent human diversity? This article is part 7 of a series about specificity testing. Be sure to read part 6, about t

Integral Molecular, a founding member of Philadelphia

Philadelphia - Integral Molecular, a founding member of Philadelphia's biotechnology community, has again been named a Top Workplace by The Philadelphia Inquirer. The honor is based entirely on confidential employee feedback and measured against national

In this article: Can off-target binding cause adverse events? What does MPA screening of clinical-stage MAbs reveal? Can secreted protein off-targets cause adverse events? Do off-targets always cause adverse events? This article is part 6 of a series abou

In this article: How common is off-target binding, really? Does polyspecificity persist into late-stage clinical development? Why can't you predict off-targets from sequence analysis alone? What is TCR missing? This article is part 5 of a series about spe

Thursday, June 25, 2026 11 am EDT View the recording Many high value therapeutic targets, particularly multipass membrane proteins, remain untapped due to technical constraints such as sequence conservation and structural complexity. In this webinar, we w

In this article: Why we developed a better specificity testing tool What advantages does the MPA offer over conventional methods? What is the ISTAND qualification process? What makes the MPA's qualification significant? This article is part of a series ab

Data-Driven Technology Re-establishes a Pathway for Antibody Genus Claims that Meet US Patent Requirements Philadelphia - Integral Molecular, the industry leader in the discovery and engineering of antibodies against membrane proteins, announces that the